Patrik Foerch appointed chief scientific officer; David Lowe, senior vice president of protein therapeutics; and Benjamin Owens, chief business officer.
Alliance will enhance cell and gene therapy pipelines from BRL Medicine from clinical trials to further expedite commercialization of innovative therapies.